UBS initiated coverage of Glaukos (GKOS) with a Buy rating and $182 price target While the shares trade at a high multiple versus peers, the premium is warranted by Glaukos’ “top-tier” growth profile, which has sales estimates tilted to the upside, the analyst tells investors in a research note. The firm says iDose is positioned to drive sales upside.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Tesla upgraded, Autodesk initiated: Wall Street’s top analyst calls
- Glaukos price target raised to $153 from $145 at Stifel
- Glaukos downgraded to Underweight from Equal Weight at Morgan Stanley
- Glaukos price target raised to $149 from $140 at BTIG
- Glaukos Revolutionizes Glaucoma Treatment with iDose TR Approval